A post hoc analysis of two phase 3 trials shows abrocitinib (Cibinqo) sustains meaningful skin clearance and itch relief through 112 weeks in patients aged 12 and older with moderate-to-severe atopic dermatitis. Both the 100 mg and 200 mg daily doses outperformed placebo at week 16, with responses holding steady long-term. No unexpected safety signals were reported.
Good news for eczema patients: abrocitinib, Pfizer's JAK1 inhibitor, continues to deliver meaningful skin clearance and itch relief well beyond the initial treatment phase. A post hoc analysis of the JADE COMPARE and JADE EXTEND phase 3 trials found that both the 100 mg and 200 mg daily doses significantly outperformed placebo at week 16 — and those gains held through 112 weeks in patients with moderate or severe atopic dermatitis (AD), including 254 adolescents.
The 200 mg dose showed an edge in severe disease, with IGA 0/1 (clear or almost clear skin) response rates of 54.5% at week 112, compared to 38.6% for the 100 mg dose. Itch relief kicked in fast — within just two weeks — and quality-of-life improvements were also sustained over time. Adverse events were more common with the higher dose but serious events and discontinuations were similar across both doses.
By the Numbers:
Why it matters: Atopic dermatitis is a chronic, relapsing condition, so long-term efficacy data are critical for both patients and clinicians. These findings support abrocitinib as a durable treatment option across disease severity levels, including in adolescents — a population often underrepresented in long-term studies.
